Document 0226
 DOCN  M9440226
 TI    HIV-1 infection incidence among persons with hemophilia in the United
       States and western Europe, 1978-1990. Multicenter Hemophilia Cohort
       Study.
 DT    9404
 AU    Kroner BL; Rosenberg PS; Aledort LM; Alvord WG; Goedert JJ; Research
       Triangle Institute, Rockville, MD 20852.
 SO    J Acquir Immune Defic Syndr. 1994 Mar;7(3):279-86. Unique Identifier :
       AIDSLINE MED/94149563
 AB    We studied human immunodeficiency virus type 1 (HIV-1) infection
       incidence over time in a 16-center cohort of hemophiliacs in the United
       States and Europe and estimated the most likely date of seroconversion
       for all seropositive subjects. Five U.S. centers enrolled subjects
       independent of HIV-1 status, whereas 11 centers preferentially included
       seropositive subjects. We obtained unbiased estimates of HIV-1 infection
       incidence rates from the five centers and estimated dates of
       seroconversion from the distribution seen among seropositives from all
       centers. In the five-center cohort, infection incidence began in 1978,
       peaked in October 1982 at 22 infections per 100 person-years at risk,
       and declined to 4 per 100 person-years by July 1984. Few infections
       occurred after 1987, and by that time, 50% of the cohort had become
       infected. Median seroconversion dates for subgroups of all seropositives
       ranged from July 1980 to December 1983, depending on the dose and type
       of factor concentrate. Median dates in Europe ranged from September 1981
       to March 1983 and reflected the use of products manufactured from
       American plasma. Infection incidence apparently peaked about the same
       time that public health interventions were introduced to reduce
       transmission. These interventions, including heat treatment of factor
       concentrates and deferral of high-risk donors, have prevented HIV-1
       infection from becoming endemic among younger birth cohorts of persons
       with hemophilia.
 DE    Adolescence  Adult  Age Factors  Child  Cohort Studies
       Europe/EPIDEMIOLOGY  Factor IX/THERAPEUTIC USE  Factor VIII/THERAPEUTIC
       USE  Hemophilia/*COMPLICATIONS/DRUG THERAPY  Human  HIV
       Infections/*EPIDEMIOLOGY/ETIOLOGY  HIV Seropositivity/EPIDEMIOLOGY
       *HIV-1  Incidence  Likelihood Functions  Male  Risk Factors  Support,
       U.S. Gov't, P.H.S.  United States/EPIDEMIOLOGY  JOURNAL ARTICLE
       MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).